Literature DB >> 10981167

Aldosterone and vascular damage.

D Duprez1, M De Buyzere, E R Rietzschel, D L Clement.   

Abstract

Although the aldosterone escape mechanism is well known, aldosterone has often been neglected in the pathophysiologic consequences of the activated renin-angiotensin-aldosterone system in arterial hypertension and chronic heart failure. There is now evidence for vascular synthesis of aldosterone aside from its secretion by the adrenal cortex. Moreover, aldosterone is involved in vascular smooth muscle cell hypertrophy and hyperplasia, as well as in vascular matrix impairment and endothelial dysfunction. The mechanisms of action of aldosterone may be either delayed (genomic) or rapid (nongenomic). Deleterious effects of aldosterone leading to vascular target-organ damage include (besides salt and water retention) decreased arterial and venous compliance, increased peripheral vascular resistance, and impaired autonomic vascular control due to baroreflex dysfunction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981167     DOI: 10.1007/s11906-000-0017-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  45 in total

1.  Vascular hypertrophy and remodeling in secondary hypertension.

Authors:  D Rizzoni; E Porteri; M Castellano; G Bettoni; M L Muiesan; P Muiesan; S M Giulini; E Agabiti-Rosei
Journal:  Hypertension       Date:  1996-11       Impact factor: 10.190

2.  Impaired baroreflex function and arterial compliance in primary aldosteronism.

Authors:  F Veglio; P Molino; G Cat Genova; R Melchio; F Rabbia; T Grosso; G Martini; L Chiandussi
Journal:  J Hum Hypertens       Date:  1999-01       Impact factor: 3.012

3.  Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells.

Authors:  M Schneider; A Ulsenheimer; M Christ; M Wehling
Journal:  Am J Physiol       Date:  1997-04

4.  Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors.

Authors:  J W Funder; P T Pearce; R Smith; J Campbell
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

5.  Essential hypertension: renin and aldosterone, heart attack and stroke.

Authors:  H R Brunner; J H Laragh; L Baer; M A Newton; F T Goodwin; L R Krakoff; R H Bard; F R Bühler
Journal:  N Engl J Med       Date:  1972-03-02       Impact factor: 91.245

Review 6.  The role of vascular steroid receptors in the control of vascular contractility and peripheral vascular resistance.

Authors:  L Kornel
Journal:  J Steroid Biochem Mol Biol       Date:  1993-04       Impact factor: 4.292

7.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Authors:  R Rocha; P N Chander; K Khanna; A Zuckerman; C T Stier
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

8.  Chronic administration of aldosterone depresses baroreceptor reflex function in the dog.

Authors:  W Wang
Journal:  Hypertension       Date:  1994-11       Impact factor: 10.190

9.  Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta.

Authors:  U Ikeda; T Kanbe; I Nakayama; Y Kawahara; M Yokoyama; K Shimada
Journal:  Eur J Pharmacol       Date:  1995-07-18       Impact factor: 4.432

10.  Aldosterone biosynthesis and action in vascular cells.

Authors:  R Takeda; H Hatakeyama; Y Takeda; K Iki; I Miyamori; W P Sheng; H Yamamoto; I A Blair
Journal:  Steroids       Date:  1995-01       Impact factor: 2.668

View more
  19 in total

Review 1.  Aldosterone as a determinant of cardiovascular and renal dysfunction.

Authors:  M Epstein
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

Review 2.  Cardiorenal disease: a clinical intersection.

Authors:  Vikram Kalra; Sandeep Mahajan; Sanjay Kumar Agarwal; Suresh Chander Tiwari
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.

Authors:  J Davies; A Gavin; M Band; A Morris; A Struthers
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

4.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

5.  Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities.

Authors:  Mohamad C N Sinno; Mouaz Al-Mallah
Journal:  Cardiol Res Pract       Date:  2010-07-01       Impact factor: 1.866

6.  Intensified inhibition of renin-angiotensin system: a way to improve renal protection?

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

7.  Endothelial cell swelling by aldosterone.

Authors:  H Oberleithner; S W Schneider; L Albermann; U Hillebrand; T Ludwig; C Riethmüller; V Shahin; C Schäfer; H Schillers
Journal:  J Membr Biol       Date:  2003-12-01       Impact factor: 1.843

Review 8.  Intensified inhibition of renin-angiotensin system: a way to improve renal protection?

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

9.  Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin.

Authors:  F E Xavier; R Aras-López; I Arroyo-Villa; L del Campo; M Salaices; L V Rossoni; M Ferrer; G Balfagón
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

10.  Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk.

Authors:  Jenifer M Brown; Patricia C Underwood; Claudio Ferri; Paul N Hopkins; Gordon H Williams; Gail K Adler; Anand Vaidya
Journal:  Hypertension       Date:  2014-03-24       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.